eFFECTOR Therapeutics Inc
F:LWK1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
eFFECTOR Therapeutics Inc
F:LWK1
|
US |
|
Lycopodium Ltd
ASX:LYL
|
AU |
Relative Value
There is not enough data to reliably calculate the relative value of LWK1.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
LWK1 Competitors Multiples
eFFECTOR Therapeutics Inc Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
eFFECTOR Therapeutics Inc
F:LWK1
|
1.1m EUR | 0 | -0 | 0.7 | 0.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.3B USD | 5.9 | 86.5 | 14.4 | 20 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.5B USD | 5.1 | 24.4 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.4B USD | 5.8 | 20 | 12.5 | 15.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.6B USD | 9.5 | 29 | 21.8 | 22.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.9B USD | 5.4 | 17.3 | 12.7 | 14.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.4B AUD | 3.1 | 34.2 | 11.3 | 14.2 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
36B EUR | 10.2 | 32.8 | 35.3 | 36.1 |